AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6771814
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no tranquilizer)
Trial: 31876397
Drug: Combined Individual
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Individual and Family Cognitive Behavioural Therapy (IFCBT)
Trial: 31422012
Drug: Contemporary drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contemporary drug-eluting stents (DES)
Trial: 22878432
Drug: Sativex (oromucosal),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sativex (oromucosal), self-titrated to symptom relief or maximum tolerated dose (maximum of 130 mg THC and 120 mg CBD daily)
Trial: 20634174
Drug: Chromium picolinate
RxNorm normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chromium picolinate 500 mcg daily
Trial: 20634174
Drug: Chromium picolinate
RxNorm normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chromium picolinate 1000 mcg daily
Trial: 19769830
Drug: Acetaminophen/codeine 600/60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen/codeine 600/60 mg
Trial: 2955899
Drug: Tetracycline 250
RxNorm normalized name: tetracycline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 250 mg BID for four months
Trial: 2955899
Drug: Erythromycin 250
RxNorm normalized name: erythromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg BID for four months
Trial: 24036849
Drug: Endurance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endurance training on a cycle-ergometer or aquatic-bike, 30 min daily at 60% of VO2peak for 3 weeks
Trial: 21502634
Drug: Danoprevir monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danoprevir monotherapy
Trial: 18032491
Drug: CD8(+) T-cell
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD8(+) T-cell peptide epitope vaccine
Trial: 9278196
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of felbamate (600 mg or 1200 mg)
Trial: 9278196
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of felbamate (600 mg or 1200 mg every 12 h)
Trial: 8350886
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (6 g daily for one year)
Trial: 25039961
Drug: Parent-mediated communication-focused
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-mediated communication-focused treatment
Trial: 21220402
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of ≥ 6 μg/day of bromodichloromethane
Trial: 11474387
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg; 2 doses) with NAP
Trial: 11474387
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg; 1 dose) with PEG-EL
Trial: 9605803
Drug: Three full
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three full doses of PRP-T or PRP-CRM197
Trial: 9605803
Drug: Fractional-dose regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional-dose regimens (one half or one third of the full dose)
Trial: 9605803
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of PRP-T
Trial: 9605803
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of PRP-CRM197
Trial: 8581408
Drug: BT 563
RxNorm normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT 563 (10 mg/day for 12 days)
Trial: 8581408
Drug: Cyclosporin (CyA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin (CyA) and low dose steroids
Trial: 340129
Drug: Intra-articular methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular methotrexate (5 mg, two injections of 2.5 mg a week apart)
Trial: 340129
Drug: Intra-articular triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular triamcinolone hexacetonide (20 mg, single injection)
Trial: 31350798
Drug: Topical autologously
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical autologously sourced PRP added to a preservative cosmetic base applied twice daily for 8 weeks
Trial: 31350798
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control serum applied twice daily for 8 weeks
Trial: 27624149
Drug: D1 receptor
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1 receptor antagonist fluphenazine (FLU; 3 mg)
Trial: 27624149
Drug: D2 receptor
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 receptor antagonist haloperidol (HAL; 3 mg)
Trial: 26051201
Drug: 12-month adherence
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month adherence program and statin medication
Trial: 26051201
Drug: Statin medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin medication only
Trial: 21943331
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplementation (SG)
Trial: 19136486
Drug: ivabradine 5
RxNorm normalized name: ivabradine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 5 mg b.i.d. for 2 months, increased to 7.5 mg b.i.d. for a further 2 months
Trial: 15508522
Drug: Dummy dentition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy dentition with simulated cavity preparation by 5 operators.
Trial: 9517642
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg t.i.d. for 2 weeks
Trial: 3191940
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg at 6 p.m. (Fam 6)
Trial: 3191940
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg at 10 p.m. (Fam 10)
Trial: 23247974
Drug: Transoral robotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transoral robotic surgery with adjuvant therapy
Trial: 21200077
Drug: Inhaled loxapine
RxNorm normalized name: loxapine Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled loxapine (5 mg)
Trial: 15583115
Drug: Metyrapone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metyrapone (1 g/d)
Trial: 11583752
Drug: Normal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal treatment and follow-up (control group)
Trial: 2897197
Drug: Tazifylline 5
RxNorm normalized name: bamifylline
DrugBank: Bamifylline (DB13203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazifylline 5 mg
Trial: 2897197
Drug: Tazifylline 10
RxNorm normalized name: bamifylline
DrugBank: Bamifylline (DB13203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazifylline 10 mg
Trial: 2897197
Drug: Tazifylline 15
RxNorm normalized name: bamifylline
DrugBank: Bamifylline (DB13203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazifylline 15 mg
Trial: 31392822
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg dulaglutide
Trial: 31392822
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg dulaglutide
Trial: 25568568
Drug: Fentanyl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (2 µg/kg IV bolus) + Nitroglycerin (400 µg/spray, 2 puffs)
Trial: 25568568
Drug: Fentanyl (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (2 µg/kg IV bolus)
Trial: 7509329
Drug: 5‐FU (5‐fluorouracil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU (5‐fluorouracil) concurrent with either 50‐52 Gy in 20‐21 or 30‐36 Gy in 10‐15 fractions (radical)
Trial: 7509329
Drug: 5‐FU (5‐fluorouracil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU (5‐fluorouracil) concurrent with either 50‐52 Gy in 20‐21 or 30‐36 Gy in 10‐15 fractions (palliative)
Trial: 25572008
Drug: nab-paclitaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel (100 mg/m2 weekly) plus carboplatin (C)
Trial: 25572008
Drug: solvent-based paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: solvent-based paclitaxel (200 mg/m2 every 3 weeks) plus carboplatin (C)
Trial: 21311897
Drug: Metoprolol CR/XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/XL at peak stress (40 μg/kg/min of dobutamine)
Trial: 21471262
Drug: Levosimendan infusion
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan infusion
Trial: 10180369
Drug: Cheaper treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cheaper treatment
Trial: 10180369
Drug: More expensive
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More expensive treatment
Trial: 22388601
Drug: Intervention Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Group (IG) - Pharmacist involvement in drug therapy management, including targeted drug counselling before discharge.
Trial: 18714239
Drug: Serial CE
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial CE (concurrent exercise)
Trial: 18714239
Drug: Integrated CE
RxNorm normalized name: Amidex ce surfactant
DrugBank: Coco diethanolamide (DB18828)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated CE (concurrent exercise)
Trial: 12515747
Drug: Intravenous levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous levosimendan (Levo)
Trial: 11269973
Drug: Antineutrophil cytoplasmic
RxNorm normalized name: c-Antineutrophil cytoplasmic antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antineutrophil cytoplasmic antibodies (ANCAs) in IBD patients
Trial: 8936353
Drug: Sinemet CR
RxNorm normalized name: Sinemet CR
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sinemet CR (50/200 mg carbidopa/mg levodopa)
Trial: 8936353
Drug: Sinemet STD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinemet STD (25/100 mg)
Trial: 1587068
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg alprazolam
Trial: 19378514
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of remifentanil (RG)
Trial: 19378514
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of sufentanil (SG)
Trial: 11165726
Drug: β-blocker therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blocker therapy in pregnancy (meta-analysis of trials)
Trial: 11165726
Drug: β-blocker therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blocker therapy in pregnancy (prospective cohort)
Trial: 9840605
Drug: Intravenous ARTS
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ARTS (120 mg)
Trial: 9840605
Drug: Oral ARTS
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ARTS (100 mg)
Trial: 2826285
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial embolization once + monthly chemotherapy with high doses of 5‐fluorouracil
Trial: 2826285
Drug: Monthly chemotherapy
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly chemotherapy with high doses of 5‐fluorouracil
Trial: 2024656
Drug: Calcium acetate
RxNorm normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium acetate (initial dose 8.11 mmol (325 mg Ca2+) per meal, adjusted to 14.6 mmol (586 mg) Ca2+ per meal)
Trial: 319141
Drug: Methylprednisolone (steroids)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (steroids)
Trial: 31416212
Drug: Cardiose® (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiose® (500 mg of 2S‐Hesperidin)
Trial: 25602164
Drug: HMLE capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMLE capsules
Trial: 24851570
Drug: Oatmeal (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oatmeal (70 g daily, 3 g beta-glucan)
Trial: 24851570
Drug: Rice porridge
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice porridge (control product, 70 g daily)
Trial: 20847731
Drug: Ice cream
RxNorm normalized name: Nice Cream 2% Topical Dental Foam (mint)
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice cream intake/kg
Trial: 20847731
Drug: Pre-ice cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-ice cream fullness
Trial: 15860518
Drug: G‐CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (5 microg/kg/day s.c. for 4 consecutive days)
Trial: 9337376
Drug: Quadrivalent rotavirus
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent rotavirus vaccine (4x10^5 plaque-forming units per dose)
Trial: 2954736
Drug: Isradipine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (15 mg/day)
Trial: 31490268
Drug: Dabigatran (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (110 mg bid)
Trial: 26109251
Drug: Dabigatran (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (150 mg bid)
Trial: 28339794
Drug: Warfarin (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (with heparin bridging)
Trial: 28339794
Drug: Warfarin (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (without heparin bridging)
Trial: 21443837
Drug: Anticoagulation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation with 40 mg of enoxaparin subcutaneously once daily for 21 days
Trial: 18493597
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment (IPTi) using sulfadoxine-pyrimethamine (SP)
Trial: 12679453
Drug: Continue GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue GH therapy (0.35 IU/kg x wk)
Trial: 12679453
Drug: Discontinue GH
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinue GH therapy
Trial: 12679453
Drug: Continue GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue GH therapy
Trial: 31597555
Drug: Telephone-based self-help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based self-help cognitive behavioural therapy (tel-CBT)
Trial: 29044032
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels higher than 50 nmol/L
Trial: 29044032
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficiency (lower than 37.5 nmol/L)
Trial: 23597811
Drug: Pre-sliced fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-sliced fruit (apples) served in treatment schools
Trial: 21678741
Drug: DTaP-IPV//PRP T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV//PRP T vaccine (Pentaxim)
Trial: 10970701
Drug: Early vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early vaccination with several doses of Hib vaccine starting at three months
Trial: 10970701
Drug: Late vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late vaccination with a single dose of Hib vaccine at two years
Trial: 8874564
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion (80 micrograms.kg-1.min-1)
Trial: 1394219
Drug: Exemestane (FCE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (FCE 24304) 25 mg
Trial: 1394219
Drug: Exemestane (FCE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (FCE 24304) 50 mg
Trial: 1394219
Drug: Exemestane (FCE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (FCE 24304) 200 mg
Trial: 1394219
Drug: Exemestane (FCE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (FCE 24304) 400 mg
Trial: 1394219
Drug: Exemestane (FCE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (FCE 24304) 800 mg
Trial: 1394219
Drug: Exemestane (FCE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (FCE 24304) (all doses)
Trial: 3903778
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg naproxen
Trial: 31870413
Drug: Immediate prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate prescription for antibiotics
Trial: 31870413
Drug: Immediate prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate prescription for antibiotics plus a 7-day course of cranberry capsules
Trial: 31870413
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry capsules plus a delayed prescription for antibiotics
Trial: 24937967
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone gel supplementation (study group, n = 71)
Trial: 24937967
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug for luteal support (control group, n = 78)
Trial: 22320449
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with almotriptan
Trial: 22320449
Drug: Non-early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-early treatment
Trial: 17950147
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose complex, 200 mg weekly for 5 weeks
Trial: 16253504
Drug: Dydrogesterone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone (10 mg b.i.d.)
Trial: 16253504
Drug: Intramuscular human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular human chorionic gonadotrophin (hCG; 5000 IU every 4 days)
Trial: 16253504
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (controls)
Trial: 9988780
Drug: MCT oil
RxNorm normalized name: Organic MCT Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT oil (71 g)
Trial: 9988780
Drug: Canola oil
RxNorm normalized name: Canola Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canola oil (71 g)
Trial: 1765893
Drug: Behaviorally based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviorally based smoking-cessation program with methadone dose increase
Trial: 28103159
Drug: Medication (methylphenidate)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (methylphenidate)
Trial: 23032060
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion at three progressively higher rates (approximately 150, 350, and 700 pmol/liter) during hyperglycemia (glucose maintained at approximately 9 mmol/liter)
Trial: 20547942
Drug: Topical voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical voriconazole (in patients with baseline BSCVA of 20/40 to 20/400)
Trial: 12080437
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Mediterranean diet and leisure time physical activity
Trial: 1771224
Drug: Atenolol (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (75 mg)
Trial: 6787141
Drug: Parenteral hyperalimentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral hyperalimentation fluids